Skip to main content
OpenTrials
Completed

NCT Number: NCT05752526

A Study of Diclofenac Gel in Women With Primary Dysmenorrhea

The goal of this clinical trial is to compare 1% and 3% diclofenac gel (DARE-PDM1) to placebo in women with symptomatic primary dysmenorrhea. The main question it aims to answer are:

Is DARE-PDM1 1%, 3% diclofenac gel systemically safe? What are the systemic levels of DARE-PDM1 1%, 3% diclofenac gel in plasma and vaginal fluid following 1 dose and 3 doses.

Participants will be seen for routine safety evaluations and complete a daily diary recording dysmenorrhea associated pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

PARC Clinical Research

Adelaide, Western Australia, Australia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females ages 18- 50 years old (inclusive)
  • Self-assessment of historic dysmenorrhea associated pain level of ≥ 5 on a scale of 0 - 10 in at least one of the following anatomic sites: pelvic/vaginal pain, low back pain, while not using NSAIDs or hormonal contraception.
  • Non-pregnant status
  • If applicable, agrees to be sexually abstinent and place nothing in the vagina during the 120 hours between visits 3 and 8 and the 3-day period of the multiple dose regimen.
  • Agrees to use adequate non-hormonal birth control during the trial (e.g. study provided male condoms without nonoxynol-9 lubricant, tubal sterilization, heterosexual abstinence) (Because hormonal birth control is a known off label treatment for dysmenorrhea, if the participant is on hormonal birth control other than Depo-Provera contraceptive injection, she agrees to discontinue it and have at least one spontaneous intervening menses before the start of the study period. If using Depo Provera, has not had an injection within the 4 months before Visit 1 and must have had a spontaneous menses prior to visit 2.)
  • Provides informed consent for participating in the trial
  • Willingness to use only study-provided oral paracetamol as rescue pain medication for dysmenorrhea, if needed according to investigator's instruction.
  • Patient is fluent in the English language.
  • Patient is capable of understanding and complying with the protocol and agrees to sign the informed consent document.
  • Patient has had a cervical screen performed within five years prior to Visit 1 and can provide documentation indicating normal test results consistent with Australian Health guidelines. If the patient cannot provide documentation, a cervical screen will be performed at Visit 1. Patients with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.

Exclusion criteria

  • Positive pregnancy test
  • Unwilling or unable to comply with protocol
  • Allergic to diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs)
  • Patients with severe liver, kidney or heart failure
  • After the use of aspirin or other nonsteroidal anti-inflammatory drugs, asthma, nasal polyps, angioedema and urticaria have occurred in the past
  • Current active peptic ulcer bleeding or perforation
  • Have a history of significant upper gastrointestinal disease
  • Have a chronic pain syndrome other than dysmenorrhea which could confound preliminary efficacy data (e.g., chronic low back pain unrelated to menses)
  • Have a positive Sexually Transmitted Infection (STI) test at screening for Chlamydia trachomatis or Neisseria gonorrhea

Treatment and study plan

Diclofenac 1%

Drug

vaginal hydrogel containing 1% Diclofenac

Diclofenac 3%

Drug

vaginal hydrogel containing 3% Diclofenac

Placebo

Drug

vaginal hydrogel, no active ingredient

Primary outcomes

  1. Measure the systemic Level of Diclofenac after a single dose of DARE-PDM1

    Time frame: 7 days

    Evaluate the plasma pharmacokinetics of diclofenac after a single dose of DARE-PDM1

  2. Measure the systemic Level of Diclofenac after three doses of DARE-PDM1

    Time frame: 3 days

    Evaluate the plasma pharmacokinetics of diclofenac after three doses of DARE-PDM1

  3. Measure the Vaginal Fluid levels of diclofenac after three doses of DARE-PDM1

    Time frame: 3 days

    Evaluate the vaginal fluid pharmacokinetics of diclofenac after three doses of DARE-PDM1

  4. Measure the Vaginal Fluid levels of diclofenac after a single dose DARE-PDM1

    Time frame: 7 days

    Evaluate the vaginal fluid pharmacokinetics of diclofenac after a single dose of DARE-PDM1

  5. Number of participants with abnormal vaginal exam findings.

    Time frame: 60 days

    Compare genital safety of DARE-PDM1 versus placebo through vaginal exams

  6. Number of participants with abnormal laboratory test results.

    Time frame: 60 days

    Evaluate systemic safety of DARE-PDM1 versus placebo through safety laboratory assessments

Other outcomes

  1. Number of participants that record a decrease in dysmenorrhea associated pain

    Time frame: 60 days

    Evaluate the efficacy of DARE-PDM1 versus placebo in reducing dysmenorrhea associated pain

  2. Use of Rescue Medications

    Time frame: 60 days

    Evaluate the number of pain medication doses needed while using DARE-PDM1

Sponsors and collaborators

Lead sponsor

Daré Bioscience, Inc.

Industry

Registry information

Official study title

A Phase 1, Multi-site, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacokinetics, Safety and Preliminary Efficacy of Two Strengths of DARE-PDM1 (1% or 3%) Versus Placebo Among Women With Symptomatic Primary Dysmenorrhea

Acronym: DARE-PDM1

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Mar 2, 2023
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.